How does Zynlonta work in the body?
Zynlonta (loncastuximab tesirine) works by targeting a specific marker on certain cancer cells and then using a built-in “payload” to kill those cells. It is an antibody-drug conjugate: the antibody part is designed to bind to CD19 on the surface of cancer cells, and the drug part is released inside the targeted cells to disrupt them and trigger cell death [1].
What does it target, and why does that matter?
Zynlonta is used for B-cell malignancies where many tumor cells express CD19. By binding CD19, the treatment aims to concentrate its cytotoxic effect on cancer cells that carry the marker, rather than affecting all cells in the body equally [1].
What happens after the antibody binds CD19?
After Zynlonta binds CD19 on a cancer cell, the antibody is taken into the cell. Inside the cell, the drug component is released and interferes with the cell’s ability to survive, leading to tumor cell death [1].
Is Zynlonta a chemotherapy or something different?
Zynlonta is not conventional chemotherapy. It is an antibody-drug conjugate, meaning it combines an antibody (for targeting) with a cytotoxic payload (for killing) [1]. That design is meant to improve targeting to CD19-positive cells.
Where does Zynlonta fit versus other CD19 therapies?
Zynlonta’s CD19-targeting approach is shared by multiple CD19-directed treatments, but the mechanism differs because Zynlonta delivers a cytotoxic payload through an antibody-drug conjugate rather than using an immune-cell product or a different CD19-binding format [1].
Sources
[1] DrugPatentWatch.com – Zynlonta (loncastuximab tesirine) https://www.drugpatentwatch.com/p/drug/zynlonta-loncastuximab-tesirine